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Establishing the expertise for rare diseases started in the
Netherlands by an inventory on existing expertise in 500
rare diseases at the Dutch Medical University Centres.
The outcome of this survey was a vast list of persons
with special knowledge of one or several of these rare
diseases. The Dutch Steering Committee on Rare Dis-
eases and Orphan Drugs concluded that differentiation
within this list was needed by defining more specialised
criteria for expertise. The criteria are based on European
directives and are in line with a future perspective to
improve quality of care. The highest distinguished level
of expertise is an Expertise Centre where basic research,
scientific output and professional training result in mul-
tidisciplinary high level care for people with complex
rare diseases. Alongside this, Expertise Teams provide
applied clinical research and high level care in local
treatment centres. Currently, the Steering Committee is
consulting professional groups, treatment centres and
other stakeholders to gain support for this plan.
In 2011, the Steering Committee will advise the Minis-
try of Health about the organisation and the quality
monitoring of the Centres of Expertise and Teams for
various rare diseases. This advice will also contain a
paragraph on a financing model concerning the organi-
sation of care for rare diseases in the Netherlands.
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